Navidea Biopharmaceuticals (NYSE:NAVB) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a research note published on Sunday. The brokerage issued a sell rating on the stock.

Navidea Biopharmaceuticals Price Performance

Shares of NAVB opened at $0.04 on Friday. The company has a market cap of $3.68 million, a price-to-earnings ratio of -0.62 and a beta of 1.13. Navidea Biopharmaceuticals has a twelve month low of $0.02 and a twelve month high of $0.28. The company has a 50 day moving average of $0.04 and a two-hundred day moving average of $0.05.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.